<DOC>
	<DOCNO>NCT01949545</DOCNO>
	<brief_summary>The purpose study compare safety efficacy carfilzomib , include measure amount study drug blood certain time follow dosing . This study do people vary degree liver function see respond differently study drug .</brief_summary>
	<brief_title>Study Pharmacokinetics Safety Carfilzomib Patients With Advanced Malignancies Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Key 1 . Relapsed progressive advanced malignancy ( solid tumor hematologic malignancy ) 2 . At least ≥ 2 prior treatment regimen underlie malignancy 3 . Confirmed advance solid tumor hematologic malignancy 4 . Measurable evaluable disease 5 . Clinical diagnosis chronic hepatic impairment stable acute worsen liver failure within one month prior enrollment . Hepatic impairment assess per National Cancer Institute Organ Dysfunction Working Group Criteria ( NCIODWG ) schema fall one follow three category : Cohort 2 ( mild ) : Bilirubin &gt; 11.5 × upper limit normal range ( ULN ) aspartate aminotransferase ( AST ) &gt; ULN , bilirubin ≤ ULN Cohort 3 ( moderate ) : ≥ 1.63 × ULN ; AST Cohort 4 ( severe ) : Bilirubin &gt; 3 × ULN ; AST Exception Inclusion Criterion # 5 Subjects Normal Hepatic Function : All subject enrol normal hepatic function ( N=10 ) must meet inclusion criterion outline exception Inclusion Criterion # 5 , substitute follow criterion enrol study : Cohort 1 ( normal hepatic function ) : Bilirubin ≤ ULN ; AST ≤ ULN 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 7 . Left ventricular ejection fraction ( LVEF ) ≥ 40 % 8 . Adequate renal function ( calculated creatinine clearance ≥ 30 mL/min ) 9 . Active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention myocardial infarction within protocolspecified period prior enrollment Key 1 . Subjects symptomatic brain metastasis central nervous system ( CNS ) disease 2 . Significant neurotoxicity ( Grade 2 pain high ) time enrolment 3 . Known human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection ( Exception : Subjects chronic clear HBV HCV infection stable liver function test [ bilirubin , AST ] allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>